335TiP Open-label, multinational, multicenter, phase IIIb/IV study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer (HER2+ BC): DESTINY-Breast12
暂无分享,去创建一个
V. Müller | G. Jerusalem | N. Niikura | G. Walker | N. Harbeck | E. Ciruelos | N. Lin | G. Viale | S. Anand | E. Oscroft